Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,829 Lymphoma
clinical trials

Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of New Orleans
mi
from
New Orleans, LA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Sanford USD Medical Center - Sioux Falls
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Providence Sacred Heart Medical Center & Children's Hospital
mi
from
Spokane, WA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Childrens National Medical Center
mi
from
Washington DC,
Click here to add this to my saved trials
Oncology Clinical Trial
The EXPLORE Trial: Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response
Status: Enrolling, Phase
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Treatment Naive Follicular Lymphoma Clinical Trial
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
Avera Cancer Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Treatment Naive Follicular Lymphoma Clinical Trial
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Treatment Naive Follicular Lymphoma Clinical Trial
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
Greenville Health System
mi
from
Greenville, SC
Click here to add this to my saved trials
Treatment Naive Follicular Lymphoma Clinical Trial
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
W VA University Mary Babb Randolph Cancer Center
mi
from
Morgantown, WV
Click here to add this to my saved trials
Treatment Naive Follicular Lymphoma Clinical Trial
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
Texas Oncology-Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
Lymphoma Clinical Trial
An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Status: Enrolling, Phase II
Updated: 12/31/1969
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Oncology Clinical Trial
A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors
Status: Enrolling
Updated: 3/22/2018
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Oncology Clinical Trial
A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors
Status: Enrolling
Updated: 3/22/2018
Borland-Groover Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Oncology Clinical Trial
A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors
Status: Enrolling
Updated: 3/22/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Oncology Clinical Trial
A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors
Status: Enrolling
Updated: 3/22/2018
Methodist Hospital Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Oncology Clinical Trial
A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors
Status: Enrolling
Updated: 3/22/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Oncology Clinical Trial
A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors
Status: Enrolling
Updated: 3/22/2018
Sibley Memorial Hospital
mi
from
Washington DC,
Click here to add this to my saved trials
Diffuse Large B-Cell Lymphoma Clinical Trial
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
Status: Enrolling, Phase III
Updated: 12/31/1969
Hematology and Oncology Associates, Inc.
mi
from
Canton, OH
Click here to add this to my saved trials
Diffuse Large B-Cell Lymphoma Clinical Trial
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
Status: Enrolling, Phase III
Updated: 12/31/1969
San Juan Oncology Associates
mi
from
Farmington, NM
Click here to add this to my saved trials
Diffuse Large B-Cell Lymphoma Clinical Trial
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
Status: Enrolling, Phase III
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Diffuse Large B-Cell Lymphoma Clinical Trial
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
Status: Enrolling, Phase III
Updated: 12/31/1969
Christiana Care Health Services, Inc
mi
from
Newark, DE
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Alaska Women's Cancer Care
mi
from
Anchorage, AK
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Kaiser Permanente-Baldwin Park
mi
from
Baldwin Park, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Billings Clinic Cancer Center
mi
from
Billings, MT
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
The Mark H. Zangmeister Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Miami Valley Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Denver Health Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Presbyterian - Saint Lukes Medical Center - Health One
mi
from
Denver, CO
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Illinois CancerCare - Eureka
mi
from
Eureka, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Lake Region Healthcare Corporation-Cancer Care
mi
from
Fergus Falls, MN
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Genesys Hurley Cancer Institute
mi
from
Flint, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
CHI Health Saint Francis
mi
from
Grand Island, NE
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Rocky Mountain Cancer Centers-Greenwood Village
mi
from
Greenwood Village, CO
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
21st Century Oncology - Henderson
mi
from
Henderson, NV
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Southeastern Medical Oncology Center-Jacksonville
mi
from
Jacksonville, NC
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada-Summerlin
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Summerlin Hospital Medical Center
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Las Vegas Cancer Center-Medical Center
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Rocky Mountain Cancer Centers-Sky Ridge
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Kaiser Permanente Los Angeles Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Saints Mary and Elizabeth Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
McKee Medical Center
mi
from
Loveland, CO
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute - Nampa
mi
from
Nampa, ID
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Ochsner Medical Center Jefferson
mi
from
New Orleans, LA
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Tulane University Health Sciences Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Yale-New Haven Hospital North Haven Medical Center
mi
from
North Haven, CT
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Illinois CancerCare - Peru
mi
from
Peru, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Providence Saint Vincent Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
St. Mary - Corwin Medical Center
mi
from
Pueblo, CO
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Spectrum Health Reed City Hospital
mi
from
Reed City, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Renown Regional Medical Center
mi
from
Reno, NV
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Marie Yeager Cancer Center
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Kaiser Permanente-San Diego Zion
mi
from
San Diego, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Sutter Pacific Medical Foundation
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Siouxland Regional Cancer Center
mi
from
Sioux City, IA
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Cox Medical Center South
mi
from
Springfield, MO
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Missouri Baptist Outpatient Center-Sunset Hills
mi
from
Sunset Hills, MO
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Rocky Mountain Cancer Centers - Thornton
mi
from
Thornton, CO
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Munson Medical Center
mi
from
Traverse City, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Marshfield Clinic - Weston Center
mi
from
Weston, WI
Click here to add this to my saved trials
Oncology Clinical Trial
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Wesley Medical Center
mi
from
Wichita, KS
Click here to add this to my saved trials
Neoplasms Clinical Trial
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
Status: Enrolling, Phase I
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Neoplasms Clinical Trial
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
Status: Enrolling, Phase I
Updated: 12/31/1969
Jefferson Medical College
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Peripheral T Cell Lymphoma Clinical Trial
Minimal Residual Disease in Peripheral T-cell Lymphoma
Status: Enrolling, Phase
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Mantle-Cell Lymphoma Clinical Trial
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)
Status: Enrolling, Phase III
Updated: 12/31/1969
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Mantle-Cell Lymphoma Clinical Trial
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)
Status: Enrolling, Phase III
Updated: 12/31/1969
Norton Cancer Institute
mi
from
Louisville, KY
Click here to add this to my saved trials
Mantle-Cell Lymphoma Clinical Trial
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)
Status: Enrolling, Phase III
Updated: 12/31/1969
Stony Brook University
mi
from
New York, NY
Click here to add this to my saved trials
Mantle-Cell Lymphoma Clinical Trial
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)
Status: Enrolling, Phase III
Updated: 12/31/1969
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Oncology Clinical Trial
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Status: Enrolling, Phase II
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Oncology Clinical Trial
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Kansas Cancer Center
mi
from
Kansas City, KS
Click here to add this to my saved trials
Oncology Clinical Trial
Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Status: Enrolling, Phase
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Auto Stem Cell Transplant for Lymphoma Patients
Status: Enrolling, Phase II
Updated: 12/31/1969
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Lymphoma Clinical Trial
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Lymphoma Clinical Trial
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
Status: Enrolling, Phase I
Updated: 12/31/1969
Tennessee Oncology - Nashville
mi
from
Nashville, TN
Click here to add this to my saved trials
Diffuse Large B-Cell Lymphoma Clinical Trial
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Diffuse Large B-Cell Lymphoma Clinical Trial
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
Texas Oncology - Austin Midtown
mi
from
Austin, TX
Click here to add this to my saved trials
Diffuse Large B-Cell Lymphoma Clinical Trial
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Click here to add this to my saved trials
Diffuse Large B-Cell Lymphoma Clinical Trial
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
University of Louisville Hospital/James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Diffuse Large B-Cell Lymphoma Clinical Trial
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
Ochsner Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Diffuse Large B-Cell Lymphoma Clinical Trial
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
Georgetown University Medical Center
mi
from
Washington DC,
Click here to add this to my saved trials
Diffuse Large B-Cell Lymphoma Clinical Trial
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Enrolling, Phase III
Updated: 12/31/1969
Shenandoah Oncology Associates, PC
mi
from
Winchester, VA
Click here to add this to my saved trials
Oncology Clinical Trial
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
1 … 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 … 98